Quantum BioPharma Ltd.

CNSX:QNTM Stock Report

Market Cap: CA$33.9m

Quantum BioPharma Management

Management criteria checks 1/4

Quantum BioPharma's CEO is Zeeshan Saeed, appointed in Jun 2023, has a tenure of 5.08 years. total yearly compensation is $896.79K, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 3.75% of the company’s shares, worth CA$1.27M. The average tenure of the management team and the board of directors is 1.8 years and 4.7 years respectively.

Key information

Zeeshan Saeed

Chief executive officer

US$896.8k

Total compensation

CEO salary percentage23.95%
CEO tenure3yrs
CEO ownership3.8%
Management average tenure1.8yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Analysis Article • Aug 09

Is Quantum BioPharma (CSE:QNTM) Using Too Much Debt?

CNSX:QNTM 1 Year Share Price vs Fair Value Explore Quantum BioPharma's Fair Values from the Community and select yours...

CEO Compensation Analysis

How has Zeeshan Saeed's remuneration changed compared to Quantum BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$31m

Dec 31 2025US$897kUS$215k

-US$26m

Sep 30 2025n/an/a

-US$29m

Jun 30 2025n/an/a

-US$27m

Mar 31 2025n/an/a

-US$21m

Dec 31 2024US$584kUS$219k

-US$14m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$600kUS$223k

-US$18m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$774kUS$239k

-US$27m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$1mUS$225k

-US$34m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$899kUS$212k

-US$28m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$249k

-US$34m

Compensation vs Market: Zeeshan's total compensation ($USD896.79K) is above average for companies of similar size in the Canadian market ($USD151.62K).

Compensation vs Earnings: Zeeshan's compensation has increased whilst the company is unprofitable.

CEO

Zeeshan Saeed (56 yo)

3yrs
Tenure
US$896,794
Compensation

Mr. Zeeshan Saeed is Independent Co-Chairman of Unbuzzd Wellness Inc. from August 01, 2023. Mr. Saeed is the CEO, Founder and Executive Co-Chair of the board at Quantum BioPharma and served as its Presiden...

Leadership Team

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Co-Founder3yrsUS$896.79k3.75%
CA$ 1.3m
Anthony Durkacz
Co-Founder & Executive Non-Independent Co-Chairman8yrsUS$896.79k2.28%
CA$ 771.5k
Donal Carroll
Chief Financial Officer1.8yrsUS$896.79k0%
CA$ 0
Nathan Coyle
Controller1.8yrsUS$185.76k0.00059%
CA$ 200.1
Andrzej Chruscinski
Vice President of Clinical & Scientific Affairsno dataUS$256.49kno data
Ashwini Joshi
Director of Pharmaceutical Developmentno dataUS$207.30kno data
Patrick Onyango
Director of Operations at U.S.no datano datano data
Jason David Sawyer
Head of Finance & Mergers and Acquisitions1.8yrsno datano data
Maryann Adesso
Corporate Secretaryno datano datano data
Randell Mack
President of FSD BioSciences5.3yrsno datano data
Kevin Cassidy
Vice President of Quality-Lucidno dataUS$144.82kno data
1.8yrs
Average Tenure
50yo
Average Age

Experienced Management: QNTM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Co-Founder5.1yrsUS$896.79k3.75%
CA$ 1.3m
Anthony Durkacz
Co-Founder & Executive Non-Independent Co-Chairman8yrsUS$896.79k2.28%
CA$ 771.5k
Kevin Harrington
Member of Advisory Board3.3yrsno datano data
Eleanor Fish
Member of Research & Clinical Advisory Board4.6yrsno datano data
Hance Clarke
Member of Research & Clinical Advisory Board4.8yrsno datano data
Eric Hoskins
Independent Director3.1yrsUS$152.99kno data
Adnan Bashir
Independent Director5yrsUS$125.87k0.0022%
CA$ 763.0
Peter Stys
Member of Research & Clinical Advisory Board4.8yrsno datano data
Albert Wong
Member of Research & Clinical Advisory Board4.8yrsno datano data
Joga Gobburu
Member of Regulatory Advisory Board4.6yrsno datano data
Mary Melnyk
Member of Regulatory Advisory Board4.6yrsno datano data
Kwok Chow
Member of the Regulatory Advisory Board4.4yrsno datano data
4.7yrs
Average Tenure
56yo
Average Age

Experienced Board: QNTM's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/30 21:11
End of Day Share Price 2026/06/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quantum BioPharma Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Karen SterlingKingswood Capital